The Prospects of the Two-Day Cardiopulmonary Exercise Test (CPET) in ME/CFS Patients: A Meta-Analysis

Eun-Jin Lim 1, Eun-Bum Kang 2, Eun-Su Jang 1 and Chang-Gue Son 1,*

1 Department of Korean Medicine, Institute of Bioscience and Integrative Medicine, Daejeon University, 62 Daehak-ro, Dong-gu, Daejeon 34520, Korea; eunjinlimsydney@gmail.com (E.-J.L.);
jang.ensu2@gmail.com (E.-S.J.)
2 Department of Health and Exercise Management, Daejeon University, 62 Daehak-ro, Dong-gu, Daejeon 34520, Korea; kbume23@naver.com
* Correspondence: ckson@dju.ac.kr; Tel: +82-42-229-6484; Fax: +82-42-257-6398

Abstract: Background: The diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is problematic due to the lack of established objective measurements. Postexertional malaise (PEM) is a hallmark of ME/CFS, and the two-day cardiopulmonary exercise test (CPET) has been tested as a tool to assess functional impairment in ME/CFS patients. This study aimed to estimate the potential of the CPET. Methods: We reviewed studies of the two-day CPET and meta-analyzed the differences between ME/CFS patients and controls regarding four parameters: volume of oxygen consumption and level of workload at peak (VO₂peak, Workloadpeak) and at ventilatory threshold (VO₂@VT, Workload@VT). Results: The overall mean values of all parameters were lower on the 2nd day of the CPET than the 1st in ME/CFS patients, while it increased in the controls. From the meta-analysis, the difference between patients and controls was highly significant at Workload@VT (overall mean: −10.8 at Test 1 vs. −33.0 at Test 2, p < 0.05), which may reflect the functional impairment associated with PEM. Conclusions: Our results show the potential of the two-day CPET to serve as an objective assessment of PEM in ME/CFS patients. Further clinical trials are required to validate this tool compared to other fatigue-inducing disorders, including depression, using well-designed large-scale studies.

Keywords: cardiopulmonary exercise test; chronic fatigue syndrome; myalgic encephalomyelitis; postexertional malaise

1. Introduction

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating multisystem disease that affects more than 20 million people of all ages and races worldwide [1,2]. The core symptoms are severe fatigue, unrefreshing sleep, postexertional malaise (PEM), and cognitive dysfunction for more than 6 months [3]. Approximately 30% of the patients are housebound, and 50% are unable to work full time [4]. Despite the seriousness of the illness, ME/CFS has no established pathophysiology or diagnostic tests yet [4]. Moreover, the diagnosis of ME/CFS is often confused with other fatigue-related or comorbid illnesses (e.g., depression) due to the overlapping symptoms [5].

Although the clinical presentation of ME/CFS can be ambiguous, a 2015 report by the Institute of Medicine (IOM) states that PEM is a hallmark of this disease and helps distinguish it from other conditions [3]. PEM consists of exertional intolerance and worsening of symptoms following minor physical or cognitive exertion, which can be severe enough to leave the patients bedridden [6,7]. Studies on the prevalence of PEM in ME/CFS reported that more than 80% of all ME/CFS patients had...
experienced this symptom at some point in their illness [8,9]. The underlying pathophysiology of PEM is not clearly understood, but researchers have adapted the two-day cardiopulmonary exercise test (CPET) as a strategy for objectively measuring PEM [3,10–12].

The CPET was developed as a tool to measure the functional capacity of the body through analysis of gas exchange (e.g., oxygen, and carbon dioxide) during exercise for athletes and people with cardiac, pulmonary, vascular, and metabolic disorders [13]. In general, the CPET is performed on a single day for the above purposes; however, the two-day CPET has received attention particularly for ME/CFS since 2007 [10]. It can assess recovery capacity using two exercise tests administered 24 h apart [14]. A number of one-day CPET studies reported a lack of significant differences between ME/CFS patients and controls [15–18]; however, significantly different responses were observed in the 2nd test of the two-day CPET [10,19,20]. This may indicate impaired recovery, reduced energy production, and likely PEM in ME/CFS patients [14]. Multiple studies have reported an association with mitochondrial dysfunction as a potential pathophysiology in ME/CFS patients [21,22].

A previous review study assessed one parameter (the volume of oxygen consumption at peak, VO2peak) between ME/CFS patients and controls by combining the two different tests (one-day and two-day CPET studies) [23]. However, considering the possible differences in the results of one-day and two-day CPET, two-day CPET data may need to be analyzed separately in various parameters. Therefore, we meta-analyzed the parameters of VO2 and workload both at peak (VO2peak, Workloadpeak) and at ventilatory threshold (VO2@VT, Workload@VT) in two-day CPET studies to assess the potential use of this test as a diagnostic tool for ME/CFS.

2. Methods

2.1. Search Strategy, Inclusion and Exclusion Criteria

We conducted a systematic search in five public databases and two search sources: PubMed, the Cochrane Library, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), Medline, Google Scholar, a hand search, and the reference lists of the included studies. The search was conducted from February to June 2020. The search keywords were ‘Chronic fatigue syndrome’ [MeSH terms] AND ‘cardiopulmonary exercise test’ or ‘CEPT’ [MeSH terms]. For the Google Scholar search in particular, we restricted the search criteria to reduce the initial abundant numbers and selected the studies not searched by PubMed. Papers were screened using the following inclusion criteria: (a) studies of cross-sectional, case–control, prospective studies that conducted the CPET to measure diagnostic parameters for ME/CFS, (b) two-day CPET with the two sessions conducted 24 h apart, (c) studies that measured the four parameters (VO2peak, Workloadpeak, VO2@VT, and Workload@VT) for the test. The exclusion criteria were as follows: (a) non clinical-based studies, (b) studies for other than ME/CFS, and studies with (c) single CPET, (d) no controls and that failed to state the four parameter values, (e) less than 5 participants, (f) studies that measured other than the four parameters. The search and data extraction were performed by E-J. L. and C-G. S., and any disagreements were resolved by discussions.

2.2. Data Extraction and Outcome Measures

The main features of the studies were extracted and compiled including; authors, year of publication, and the number of participants, the age and body mass index (BMI) of the participants, and the methodology of selecting the participants (Table 1). The primary outcome measures were the four parameters: VO2peak, Workloadpeak, VO2@VT, and Workload@VT. These parameters are involved in measuring activity limitations of ME/CFS patients [24]. These are defined as follows: (1) VO2peak is the highest value of oxygen uptake obtained during the exercise. (2) VO2 at ventilatory threshold (VT) is the volume of oxygen at VT, which is the point which ventilation starts to increase at a faster rate than oxygen consumption. (3) Workloadpeak is the power output produced by the participant at peak. (4) Workload@VT is the level of power output produced at VT [11,14].
2.3. Statistical Analysis

We calculated the mean difference and meta-analyzed the four parameters of ME/CFS patients and controls as of Testes 1 and 2 (Tables 2–4). The four parameters was estimated with a random-effects model to account for the heterogeneity of the data, and we compared the $I^2$ and significance ($p$ values) of those groups. $I^2$ higher than 50% is considered substantially heterogeneous [25]. A forest plot was used to show the estimated overall mean number of the parameters, and $p$ value < 0.05 is considered significant. The data were analyzed using the meta-analysis program version 5.3 Review Manager (The Cochrane Collaboration, Oxford, UK) [26].

2.4. Assessment of Quality of Studies

The quality of studies included was assessed according to the Newcastle Ottawa Scale (NOS) guideline for case-control studies, which judges studies on the following perspectives: selection of the groups, the comparability of the groups, and the ascertainment of exposure [27] (Table 1).

3. Results

3.1. Characteristics of Included Studies

In total, 218 studies were initially selected as candidates for this meta-analysis; ultimately, 5 studies were included (Figure 1). All studies used the same study protocol (an incremental cycling protocol with an interval of 24 h) and case definition (Fukuda) for inclusion of participants. Two studies additionally used the International Consensus Criteria (ICC) [28] and/or the Canadian Consensus Criteria (CCC) [6]. The total number of participants across the five studies was 98 ME/CFS patients (90 female and 8 male) and 51 controls (45 female and 6 male). The total mean age and BMI of the participants were comparable between the patient and control groups (Table 1).

![Figure 1. Flow chart of the study selection process.](source-url)
Table 1. Characteristics and assessment of quality of studies.

|                      | ME/CFS + | Control | Newcastle Ottawa Scale § |
|----------------------|----------|---------|-------------------------|
|                      |          |         | S  C  E                  |
| No. of studies       | 5        | 5       | 1  2  3  4  5  6  7  8   |
| No. of participants  | 98 (90/8)| 51 (45/6)|                       |
| (Female/Male)        |          |         |                         |
| Age (y) *            | 42.3 ± 11.6 | 41.3 ± 12.4 |                     |
| BMI (kg/m²) *        | 25.3 ± 4.8  | 25.6 ± 4.2  |                     |

### Selection of participants

|                      | ME/CFS | Control |
|----------------------|--------|---------|
| Van Ness (2007) [10] | Physician diagnosis and Fukuda | Healthy sedentary |
| Vermeulen (2010) [19]| CDC-SI 59.5 ± 13.1 † Fukuda, infectious disease onset | CDC-SI 5.0 ± 4.5 |
| Snell (2013) [29]    | Sedentary * Fukuda, Presence of PEM | Sedentary * |
| Hodges (2017) [30]   | Fukuda, (CCC and ICC) α De Paul Questionnaire, SF-36 | Healthy |
| Nelson (2019) [20]   | Physician diagnosis Fukuda/(CCC/ICC) α | Sedentary ‡ |

+ ME/CFS, Myalgic encephalomyelitis/chronic fatigue syndrome. † A star system at the included studies are judged on 3 perspectives: S, selection of groups. C, comparability of groups. E, exposure. CDC-SI, Centers for Disease Control and Prevention-Symptom Inventory questionnaire. § Estimated from the mean ages of the individual studies. * checked and confirmed. † Four ME/CFS fatigue symptoms ≥7.5. ‡ <30 min exercise/week. † <150 min of moderate exercise/week. α CCC, Canadian consensus criteria. ICC, International consensus criteria.
Table 2. Studies that performed the two-day cardiopulmonary exercise test (CPET) in ME/CFS patients and controls.

|   | Study                         | Participants (Patients/Controls) | VO$_{2peak}$ (mL kg$^{-1}$ min$^{-1}$) | VO$_{2}$@VT (mL kg$^{-1}$ min$^{-1}$) | Workload$_{peak}$ (Watt) | Workload@VT (Watt) |
|---|-------------------------------|----------------------------------|----------------------------------------|--------------------------------------|--------------------------|------------------|
| 1 | Van Ness (2007) [10]          | 6(F)                             | 26.2 ± 4.9/20.5 ± 1.8 (−5.8)           | 15.0 ± 4.9/11.0 ± 3.4 (−4.0)         | -                        | -                |
|   |                               | 6(F)                             | 28.4 ± 7.2/28.9 ± 8.0 (+0.5)            | 17.6 ± 4.9/18.0 ± 5.3 (+0.4)         | -                        | -                |
| 2 | Vermeulen (2010) [19]         | 15(F)                            | 22.3 ± 5.7/20.9 ± 5.5 (−1.3)           | 12.8 ± 3.0/11.9 ± 2.9 (−0.9)         | 132.0 ± 30.0/125.0 ± 35.0 (−7.0) | 58.6 ± 24.2/54.5 ± 20.9 (−4.1) |
|   |                               | 15(F)                            | 31.2 ± 7.0/31.9 ± 7.4 (+0.7)            | 16.7 ± 4.0/18.0 ± 4.6 (+1.3)         | 188.0 ± 46.0/196.0 ± 51.0 (+8.0) | 82.9 ± 29.1/92.9 ± 31.4 (+10.0) |
| 3 | Snell (2013) [29]             | 51(F)                            | 21.5 ± 4.1/20.4 ± 4.5 (−1.1)           | 12.7 ± 2.9/11.4 ± 2.9 (−1.3)         | 109.6 ± 28.9/101.6 ± 30.7 (−8.0) | 49.5 ± 20.4/22.2 ± 18.1 (−27.3) |
|   |                               | 10(F)                            | 25.0 ± 4.4/24.0 ± 4.3 (−1.0)           | 13.8 ± 2.8/14.1 ± 3.3 (+0.3)         | 137.2 ± 23.2/140.0 ± 25.0 (+2.8) | 58.0 ± 16.7/63.5 ± 19.5 (+5.5) |
| 4 | Hodges (2017) [30]            | 9(F)/1(M)                        | 25.0 ± 8.9/26.3 ± 7.8 (+1.3)           | 21.0 ± 4.3/22.2 ± 6.2 (+1.2)         | 135.0 ± 43.0/126.0 ± 45.0 (−9.0) | 105.0 ± 30.0/93.0 ± 37.0 (−12.0) |
|   |                               | 9(F)/1(M)                        | 32.0 ± 10.9/33.1 ± 12.5 (+1.1)         | 23.6 ± 9.0/28.5 ± 12.5 (+4.9)        | 164.0 ± 40.0/167.0 ± 41.0 (+3.0) | 119.0 ± 28.0/132.0 ± 42.0 (+13.0) |
| 5 | Nelson (2019) [20]            | 9(F)/7(M)                        | 27.3 ± 9.2/27.4 ± 8.8 (+0.1)           | 15.9 ± 4.1/15.4 ± 3.4 (−0.5)         | 154.4 ± 56.0/152.5 ± 51.7 (−1.9) | 87.8 ± 29.6/72.5 ± 27.7 (−15.3) |
|   |                               | 5(F)/5(M)                        | 29.9 ± 6.1/30.3 ± 6.2 (+0.4)           | 16.5 ± 2.0/15.9 ± 1.5 (−0.6)         | 172.0 ± 35.5/174.0 ± 36.6 (+2.0) | 90.5 ± 17.1/88.0 ± 16.7 (−13.0) |
|   | Total 90(F)/8(M)              |                                  | 24.5 ± 6.6/23.1 ± 5.7 (−1.4)           | 15.5 ± 3.8/14.4 ± 3.8 (−1.1)         | 132.8 ± 39.5/126.3 ± 40.6 (−6.5) | 75.2 ± 26.1/60.6 ± 25.9 (−14.6) |
|   |                               | 45(F)/6(M)                       | 29.3 ± 7.1/29.6 ± 7.7 (+0.3)           | 17.6 ± 4.5/18.9 ± 5.4 (+1.3)         | 165.3 ± 36.2/169.3 ± 38.4 (+4.0) | 87.6 ± 22.7/94.1 ± 27.4 (+6.5) |

ME/CFS, Myalgic encephalomyelitis/chronic fatigue syndrome. VO$_{2peak}$, Volume of oxygen uptake at peak. @VT, at ventilatory threshold. The units of parameter for VO$_2$ is mL kg$^{-1}$ min$^{-1}$, and for Workload is Watt. F, female. M, male. All results are rounded to one decimal place. Exercise mode: cycle ergometer.
Table 3. Meta-analysis of two-day CPET (test 2–test 1) for the comparisons between the ME/CFS patients and controls.

| # | Study                  | Weight (%) | Mean Difference |   |   |   |   |   |   |
|---|------------------------|------------|----------------|---|---|---|---|---|---|
|   |                        |            | VO\textsubscript{2peak} | @VT | WL\textsubscript{peak} | @VT | WL\textsubscript{peak} | @VT |   |
| 1 | Van Ness (2007) [10]   | P          | 16             | 3.5 | -  | -  | -5.7 (−1.5, −9.9)      | -4.0 (0.8, −8.8) | -  | -  |
|   |                        | C          | 8.2            | 4.3 | -  | -  | 0.5 (9.1, −8.1)        | 0.4 (6.2, −5.4)  | -  | -  |
| 2 | Vermeulen (2010) [19]  | P          | 17.1           | 17.9 | 17.2 | 26.2 | −0.9 (1.2, −3.0)       | −1.4 (2.6, −5.4) | −7.0 (16.3, −30.3) | −4.1 (12.1, −20.3) |
|   |                        | C          | 23.0           | 15.0 | 17.0 | 18.4 | 0.7 (5.9, −4.5)        | 1.3 (4.4, −1.8)  | 8.0 (42.8, −26.8)  | 10.0 (31.6, −11.6)  |
| 3 | Snell (2013) [29]      | P          | 53.1           | 63.1 | 69.8 | 38.6 | −1.1 (0.6, −2.8)       | −1.3 (−0.2, −2.4) | −8.0 (3.6, −19.6)  | −27.3 (−19.8, −34.8) |
|   |                        | C          | 42.0           | 19.8 | 46.0 | 33.8 | −1.0 (2.8, −4.8)       | 0.3 (3.0, −2.4)  | 2.8 (23.9, −18.3)  | 5.5 (21.4, −10.4)  |
| 4 | Hodges (2017) [30]     | P          | 5.9            | 3.7  | 6.3  | 13.4 | 1.3 (8.6, −6.0)        | 1.2 (3.9, −3.5)  | −9.0 (29.6, −47.6) | −12.0 (17.5, −41.5) |
|   |                        | C          | 5.8            | 1.6  | 16.3 | 8.7  | 1.1 (11.4, −9.2)       | 4.9 (14.5, −4.7) | 3.0 (38.5, −32.5)  | 13.0 (44.3, −18.3) |
| 5 | Nelson (2019) [20]     | P          | 7.9            | 11.7 | 6.7  | 21.7 | 0.1 (6.3, −6.1)        | −0.5 (2.1, −3.1) | −1.9 (35.5, −39.3) | −15.3 (4.6, −35.2) |
|   |                        | C          | 21.0           | 59.4 | 20.6 | 39.0 | 0.4 (5.8, −5.0)        | −0.6 (1.0, −2.2) | 2.0 (33.6, −29.6)  | −2.5 (12.3, −17.3) |

Overall values for P

| Heterogeneity (I^2) | p value |   |   |   |   |   |   |   |   |
|---------------------|---------|---|---|---|---|---|---|---|---|
| 19%                 | 0.30    | 0%| 0%| 60%| 0.06 | −1.7 (0.2, −3.5)       | −1.1 (−0.2, −2.0) | −7.5 (2.2, −17.2)  | −16.6 (−3.6, −29.5) |

Overall values for C

| Heterogeneity (I^2) | p value |   |   |   |   |   |   |   |   |
|---------------------|---------|---|---|---|---|---|---|---|---|
| 0%                  | 0.98    | 0%| 0%| 0%| 0.71 | −0.1 (2.4, −2.5)       | −0.01 (1.2, −1.2) | 3.6 (17.9, −10.8)  | 3.9 (13.1, −5.4)  |

P vs. C p value 0.23 0.10 0.83 0.01 **

ME/CFS, Myalgic encephalomyelitis/chronic fatigue syndrome. CPET, Cardiopulmonary exercise testing. #, Number of studies. VO\textsubscript{2peak}, volume of oxygen uptake at peak. @VT, at ventilatory threshold. WL\textsubscript{peak}, workload at peak. The units of parameter for VO\textsubscript{2} is mL × kg\(^{-1}\) × min\(^{-1}\), and for Workload or WL is Watt. P, patient. C, control. All results are rounded to one decimal place. **, p value < 0.01.
Table 4. Meta-analysis (of ME/CFS patient control) for the comparisons between the two-day CPET 1 and 2.

| #  | Study                  | Weight (%) | Mean Difference          |   |   |   |   |   |
|----|------------------------|------------|--------------------------|---|---|---|---|---|
|    |                        |            | VO_{2peak} @VT WL_{peak} @VT | VO_{2peak} @VT |   | VO_{2peak} @VT |
| 1  | VanNess (2007) [19]    | T1         | 11.9                     | 5.4 | - | - | -2.2 (-9.2, 4.8) | -2.6 (-8.1, 2.9) | - |
|    |                        | T2         | 16.4                     | 15  | - | - | -8.4 (-14.7, -1.8) | -7.0 (-12.0, -2.0) | - |
| 2  | Vermeulen (2010) [19]  | T1         | 23.4                     | 23.9 | 22.8 | 18.7 | -8.9 (-13.37, -4.3) | -3.9 (-6.4, -1.4) | -56.0 (-83.79, -28.2) | -24.3 (-43.5, -5.2) |
|    |                        | T2         | 23.1                     | 23.9 | 22.3 | 25.5 | -11.0 (-15.7, -6.3) | -6.1 (-8.9, -3.4) | -71.0 (-102.3, 39.7) | -38.4 (-57.4, -19.4) |
| 3  | Snell (2013) [29]      | T1         | 41.0                     | 39.3 | 47.2 | 49.5 | -3.5 (-6.5, -0.6) | -1.1 (-3.0, 0.8) | -27.6 (-44.0, -11.2) | -8.5 (-20.3, 3.3) |
|    |                        | T2         | 31.0                     | 26.3 | 40.5 | 34.8 | -3.6 (-6.5, -0.7) | -2.7 (-4.9, -0.5) | -38.4 (-56.0, -20.8) | -41.3 (-54.4, -28.2) |
| 4  | Hodges (2017) [30]     | T1         | 8.0                      | 4.3 | 14.6 | 10.6 | -7.0 (-15.7, 1.7) | -2.6 (-8.8, 3.6) | -29.0 (-65.4, 7.4) | -14.0 (-39.4, 11.4) |
|    |                        | T2         | 10.5                     | 7.4 | 17.2 | 11.6 | -6.8 (-15.9, 2.3) | -6.3 (-15.0, 2.4) | -41.0 (-78.7, -3.3) | -39.0 (-73.7, -4.3) |
| 5  | Nelson (2019) [20]     | T1         | 15.8                     | 27.1 | 15.4 | 21.2 | -2.6 (-8.5, 3.3) | -0.6 (-3.0, 1.8) | -17.6 (-52.8, 17.6) | -2.7 (-20.7, 15.3) |
|    |                        | T2         | 18.9                     | 27.4 | 20.0 | 28.2 | -2.9 (-8.7, 2.9) | -0.5 (-2.4, 1.4) | -21.5 (-55.5, 12.5) | -15.5 (-32.6, 1.6) |
|    | Overall values for T1  |            |                          | 22% | 7% | 21% | 0% | -4.8 (-7.3, -2.2) | -1.8 (-3.1, -0.5) | -3 -32.7 (-47.6, -17.8) | -10.8 (-19.1, -2.5) |
|    | Heterogeneity (I^2)    |            |                          | 0.27 | 0.37 | 0.28 | 0.41 | -4.8 (-7.3, -2.2) | -1.8 (-3.1, -0.5) | -3.327 (-47.6, -17.8) | -10.8 (-19.1, -2.5) |
|    | T1 p value             |            |                          | 0.42 | 0.14 | 0.46 | 0.03 * | -4.8 (-7.3, -2.2) | -1.8 (-3.1, -0.5) | -3.327 (-47.6, -17.8) | -10.8 (-19.1, -2.5) |
|    | Overall values for T2  |            |                          | 53% | 72% | 38% | 50% | -6.3 (-9.8, -2.9) | -3.8 (-6.5, -1.1) | -42.8 (-61.0, -24.5) | -33.0 (-46.4, -19.6) |
|    | Heterogeneity (I^2)    |            |                          | 0.07 | 0.01 * | 0.18 | 0.11 | -6.3 (-9.8, -2.9) | -3.8 (-6.5, -1.1) | -42.8 (-61.0, -24.5) | -33.0 (-46.4, -19.6) |
|    | T2 p value             |            |                          | 0.42 | 0.14 | 0.46 | 0.03 * | -6.3 (-9.8, -2.9) | -3.8 (-6.5, -1.1) | -42.8 (-61.0, -24.5) | -33.0 (-46.4, -19.6) |

ME/CFS, Myalgic encephalomyelitis/chronic fatigue syndrome. CPET, Cardiopulmonary exercise testing. VO_{2peak}, volume of oxygen uptake at peak. @VT, at ventilatory threshold. WL_{peak}, workload at peak. The units of parameter for VO_{2} is mL kg^{-1} min^{-1}, and for Workload or WL is Watt. T1, Test 1. T2, Test 2. All results are rounded to one decimal place. *, p value < 0.05. **, p value < 0.01.
3.2. Comparisons of the Four Parameters

The four parameters as of Test 1 and Test 2, as well as their differences between sessions, are summarized in Table 2. From Test 1 to Test 2, all four measures (VO$_{2\text{peak}}$, VO$_{2@VT}$, Workload$_{\text{peak}}$, and Workload$_{@VT}$) increased in the control group but decreased in the patient group. Among the four parameters, the Workload$_{@VT}$ of the patient group showed an especially marked decrease on Test 2 compared to Test 1, with a difference (Test 2–Test 1) of $-14.6$ in patients and $+6.5$ in controls (Table 2).

3.3. Outcomes of Meta-Analysis

From the meta-analysis, we evaluated the differences in parameters from Test 2 to Test 1 in ME/CFS patients compared to the control group (Figure 2). The values of all four parameters increased as of the 2nd test (Test 2) in the control group, while ME/CFS patients showed notable decreases in all parameters at Test 2 (Figure 2, Tables 2 and 3).

Figure 2. Meta analyzed overall mean differences of the four parameters (A-D) from the scores of the two-day CPET (test 2–test 1) for the ME/CFS (Myalgic encephalomyelitis/chronic fatigue syndrome) patients and controls: (A). VO$_{2\text{peak}}$, (B). VO$_{2@VT}$, (C). Workload$_{\text{peak}}$, (D). Workload$_{@VT}$. $p$, $p$ value. Refer to Table 3 for details.
In general, the differences between patients and controls were greater at VT than at peak and greater for workload than for VO\textsubscript{2} (Figures 2 and 3). From the meta-analysis focused on the difference between Test 2–Test 1 (using the data from patients and controls), Workload@VT showed the most notable significant difference ($p < 0.05$) (Figures 2 and 3).

4. Discussion

From our meta-analysis of five studies of two-day CPET, we identified the following three key features. First, ME/CFS patients appeared to have lower levels of all parameters than controls, especially on Test 2. Second, on Test 2, the difference between the patients and controls was observed to be larger at VT than at peak. Third, on a more specific level, Workload@VT was notably different between the two tests and between the two groups (Figures 2 and 3, Tables 2–4). These data may indicate the potential of Workload@VT value as an objective measurement in ME/CFS.

The reduced levels of parameters in the ME/CFS patient group on Test 2 shows that they failed to reproduce their work capacity from Test 1 [19]. Such reduced work capacity in general is
likely linked to a lack of cellular adenosine triphosphate (ATP) production, which normally occurs through aerobic and anaerobic metabolism [31]. Imbalanced ATP production can be caused by functional impairment of mitochondria in patients with ME/CFS [32]. Studies have reported conflicted results regarding mitochondrial impairment; some have provided evidence of actual mitochondrial dysfunction affecting oxidative phosphorylation [21,33], while other studies found no abnormal indicators of altered mitochondrial function or mitochondrial DNA mutation [19,34,35]. In fact, a number of researchers suggested a possible problem in the pathway of oxygen or glucose transportation into the cells, which may inhibit the function of mitochondria in ME/CFS patients [10,19,29,30,35,36]. The hypothesized factors inhibiting mitochondria ATP production include viral/bacterial infection [37], high levels of proinflammatory cytokines [38], reactive oxygen species (ROS) [39], and decreased levels of enzymes (such as pyruvate dehydrogenase, PDH) needed in the process of aerobic cellular respiration [40].

Lower work capacity on Test 2 than on Test 1 seems to be a unique feature of ME/CFS and is indicated as a cardinal feature for the diagnosis of PEM [3]. Patients with lung, heart, or kidney diseases presented no significant differences between Tests 1 and 2 in repeated CPETs [41–43]. Moreover, patients with other fatigue-inducing conditions such as multiple sclerosis (MS) and positive human immunodeficiency virus (HIV) status showed improved Workload@VT values on Test 2, in contrast to ME/CFS patients [30,44]. The present meta-analysis consists exclusively of data from studies containing control groups. Several other studies, despite having no control groups with larger patient group [45,46], and male ME/CFS patient group [46], produced similar outcomes, with ME/CFS patients’ lower values of Workload@VT on Test 2 than on Test 1.

Although mitochondria-associated alterations have been observed, the underlying pathophysiology of PEM has not been explored in detail. Most recently, several groups have investigated metabolic changes in ME/CFS patients with PEM [12,47]. Naviaux et al. found reduced concentrations of specific metabolites in the plasma of 45 ME/CFS patients [47]. McGregor et al. also found altered glycolysis, a low level of acetate, and a positive correlation between urine metabolites and the severity of PEM [12]. These metabolite-based findings have been applied to the development of diagnostic tools. The metabolic response showed high validity in a diagnostic test for ME/CFS, achieving accuracy of over 95% [47]. Esfandyarpour et al. demonstrated the use of a nanoneedle to measure a metabolite-based biomarker from a small volume of blood in ME/CFS patients [48]. The present data might support a link between PEM symptom and alterations in metabolism and mitochondrial ATP production in ME/CFS.

5. Conclusions

The meta-analysis indicates a significant alteration of workload at VT especially on the 2nd day of CPET in ME/CFS patients. Accordingly, the two-day CPET could be considered as one of the potential objective assessment tools for PEM in ME/CFS patients. The present study may be of value in suggesting a direction for the development of ME/CFS diagnostic tools. However, we should consider the limitations of this study, the relatively small number of participants and the studies included. Additionally, the absence of percent predicted values for different genders should also be noted as another weak point of this study. For further studies, the following should be cautiously considered: the selection of the participants using appropriate diagnostic criteria, the severity of symptoms, the comparison of males and females, and the comparison with other fatigue-inducing disorders. Studies at larger scales with more rigorous methodology are needed.

Author Contributions: E.-J.L. searched the literature, analyzed the extracted data, and wrote manuscript. E.-B.K. and E.-S.J. participated in discussion. C.-G.S. supported writing manuscript. All authors agreed to publish the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the National Research Foundation of Korea (NRF) funded by the Oriental Medicine R&D Project (NRF-2018R1A6A1A03025221).

Conflicts of Interest: There are no potential conflict of interest to disclose.
References

1. Osoba, T.; Pheby, D.; Gray, S.; Nacul, L. The Development of an Epidemiological Definition for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *J. Chronic Fatigue Syndr.* 2007, 14, 61–84.

2. American ME and CFS Society. How Many People Have ME/CFS? American ME and CFS Society U.S. (U.S.): 2019. Available online: https://ammes.org/how-many-people-have-mecfs/ (accessed on 30 June 2019).

3. Institute of Medicine of the National Academies. *Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Redefining an Illness*; Committee on the Diagnostic Criteria for ME/CFS; Institute of Medicine: Washington, DC, USA; The National Academies Press: Washington, DC, USA, 2015.

4. Bethesda, M. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Research. Workshop Report. In *State of the Knowledge Workshop*; National Institutes of Health (Maryland, U.S.): Bethesda, MD, USA, 2011.

5. Devasahayam, A.; Lawn, T.; Murphy, M.; White, P.D. Alternative diagnoses to chronic fatigue syndrome in referrals to a specialist service: Service evaluation survey. *JRSM Short Rep.* 2012, 3, 4. [PubMed]

6. Carruthers, B.M.; Jain, A.K.; De Meirleir, K.L.; Peterson, D.L.; Klimas, N.G.; Lerner, A.M.; Bested, A.C.; Flor-Henry, P.; Joshi, P.; Powles, A.P.; et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *J. Chronic Fatigue Syndr.* 2003, 11, 7–115.

7. Food and Drug Administration (FDA). *The Voice of the Patient: Chronic Fatigue Syndrome and Myalgic Encephalomyelitis*; Center for Drug Evaluation and Research (CDER); Bethesda, MD, USA, 2013.

8. Jason, L.A.; Porter, N.; Hunnell, J.; Brown, A.; Rademaker, A.; Richman, J.A. A natural history study of chronic fatigue syndrome. *Rehabil. Psychol.* 2011, 56, 32–42.

9. Jason, L.A.; Sunquist, M.; Brown, A.; Evans, M.; Vernon, S.D.; Furst, J.D.; Simonis, V. Examining case definition criteria for chronic fatigue syndrome and myalgic encephalomyelitis. *Fatigue* 2014, 2, 40–56.

10. Van Ness, J.M.; Snell, C.R.; Stevens, S.R. Diminished Cardiopulmonary Capacity during Post-Exertional Malaise. *J. Chronic Fatigue Syndr.* 2007, 14, 77–85.

11. Alla, E. Decoding the 2-Day Cardiopulmonary Exercise Test (CPET) in Chronic Fatigue Syndrome (ME/CFS). Health Rising Finding Answers for ME/CFS and FM. 2019. Available online: https://www.healthrising.org/blog/2019/01/17/decoding-2-day-cpet-chronic-fatigue-syndrome/ (accessed on 15 February 2020).

12. McGregor, N.R.; Armstrong, C.W.; Lewis, D.P.; Gooley, P.R. Post-Exertional Malaise Is Associated with Hypermetabolism, Hypoacytlation and Purine Metabolism Deregulation in ME/CFS Cases. *Diagn. (BaselSwitz.)* 2019, 9, 90.

13. Albouaini, K.; Egred, M.; Alahmar, A.; Wright, D.J. Cardiopulmonary exercise testing and its application. *Postgrad. Med. J.* 2007, 83, 675–682.

14. Stevens, S.; Snell, C.; Stevens, J.; Keller, B.; VanNess, J.M. Cardiopulmonary Exercise Test Methodology for Assessing Exertion Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Front. Pediatr.* 2018, 6, 242.

15. Bazelmans, E.; Bleijenberg, G.; Van Der Meer, J.W.; Folgering, H. Is physical deconditioning a perpetuating factor in chronic fatigue syndrome? A controlled study on maximal exercise performance and relations with fatigue, impairment and physical activity. *Psychol. Med.* 2001, 31, 107–114.

16. Cook, D.B.; Nagelkirk, P.R.; Peckerman, A.; Poluri, A.; Lamancia, J.J.; Natelson, B.H. Perceived exertion in fatiguing illness: Civilians with chronic fatigue syndrome. *Med. Sci. Sports Exerc.* 2003, 35, 563–568. [PubMed]

17. Cook, D.B.; Nagelkirk, P.R.; Peckerman, A.; Poluri, A.; Lamancia, J.J.; Natelson, B.H. Perceived exertion in fatiguing illness: Gulf War veterans with chronic fatigue syndrome. *Med. Sci. Sports Exerc.* 2003, 35, 569–574. [PubMed]

18. Moneghetti, K.J.; Shiri, M.; Contreporis, K.; Kobayashi, Y.; Maelker, H.; Davis, M.; Snyder, M.; Haddad, F.; Montoya, J.G. Value of Circulating Cytokine Profiling During Submaximal Exercise Testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Sci. Rep.* 2018, 8, 2779. [PubMed]

19. Vermeulen, R.C.W.; Kurk, R.M.; Visser, F.C.; Sluiter, W.; Scholle, H.R. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. *J. Transl. Med.* 2010, 8, 93.

20. Nelson, M.J.; Buckley, J.D.; Thomson, R.L.; Clark, D.; Kwiatek, R.; Davison, K. Diagnostic sensitivity of 2-day cardiopulmonary exercise testing in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *J. Transl. Med.* 2019, 17, 80.
21. Myhill, S.; Booth, N.E.; McLaren-Howard, J. Chronic fatigue syndrome and mitochondrial dysfunction. *Int. J. Clin. Exp. Med.* 2009, 2, 1–16.

22. Booth, N.E.; Myhill, S.; McLaren-Howard, J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). *Int. J. Clin. Exp. Med.* 2012, 5, 208–220.

23. Franklin, J.D.; Atkinson, G.; Atkinson, J.M.; Batterham, A.M. Peak oxygen uptake in chronic fatigue syndrome/myalgic encephalomyelitis: A meta-analysis. *Int. J. Clin. Exp. Med.* 2019, 40, 77–87.

24. Jones, D.E.; Hollingsworth, K.G.; Jakovljevic, D.G.; Fattakhova, G.; Pairman, J.; Blamire, A.M.; Trenell, M.I.; Newton, J.L. Loss of capacity to recover from acidosis on repeat exercise in chronic fatigue syndrome: A case-control study. *Eur. J. Clin. Investig.* 2012, 42, 186–194.

25. Higgins, J.P. T.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. *Stat. Med.* 2002, 21, 1539–1558.

26. The Cochrane Collaboration. *Review Manager (RevMan)*; Computer program, Version 5.3; The Cochrane Collaboration: London, UK, 2020.

27. Wells, G.A.; Shea, B.; O’Connell, D.; Peterson, J.; Welch, V.; Losos, M.; Tugwell, P. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomized Studies in Meta-Analyses. Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 20 June 2020).

28. Carruthers, B.M.; van de Sande, M.I.; De Meirleir, K.L.; Klimas, N.G.; Broderick, G.; Mitchell, T.; Staines, D.; Powles, A.P.; Speight, N.; Vallings, R.; et al. Myalgic encephalomyelitis: International Consensus Criteria. *J. Intern. Med.* 2011, 270, 327–338. [CrossRef] [PubMed]

29. Snell, C.R.; Stevens, S.R.; Davenport, T.E.; Van Ness, J.M. Discriminative Validity of Metabolic and Workload Measurements for Identifying People with Chronic Fatigue Syndrome. *Phys. Ther.* 2013, 93, 1484–1492. [CrossRef] [PubMed]

30. Hodges, L.D.; Nielsen, T.; Baken, D. Physiological measures in participants with chronic fatigue syndrome, multiple sclerosis and healthy controls following repeated exercise: A pilot study. *Clin. Physiol. Funct. Imaging* 2018, 38, 639–644. [CrossRef] [PubMed]

31. Spriet, L.L. Anaerobic metabolism during exercise. In *Exercise Metabolism*, 2nd ed.; Hargreaves, M., Spriet, L.L., Eds.; Human Kinetics: Champaign, IL, USA, 2006; pp. 7–27.

32. Stephens, C. *MEA Summary Review: The role of Mitochondria in ME/CFS*; The ME Association: Buckinghamshire, UK, 12 July 2019; Available online: https://meassociation.org.uk/2019/07/mea-summary-review-the-role-of-mitochondria-in-me-cfs-13-july-2019/ (accessed on 10 July 2020).

33. Tomas, C.; Brown, A.; Strassheim, V.; Elson, J.L.; Newton, J.; Manning, P. Cellular bioenergetics is impaired in patients with chronic fatigue syndrome. *PLoS ONE.* 2017, 12, e0186802. [CrossRef] [PubMed]

34. Billing-Ross, P.; Germain, A.; Ye, K.; Keinan, A.; Gu, Z.; Hanson, M.R. Mitochondrial DNA variants correlate with symptoms in myalgic encephalomyelitis/chronic fatigue syndrome. *J. Transl. Med.* 2016, 14, 19. [CrossRef] [PubMed]

35. Tomas, C.; Elson, J.L. The role of mitochondria in ME/CFS: A perspective. *Fatigue Biomed. Health Behav.* 2019, 7, 52–58. [CrossRef]

36. Lawson, N.; Hsieh, C.-H.; March, D.; Wang, X. Elevated Energy Production in Chronic Fatigue Syndrome Patients. *J. Nat. Sci.* 2016, 2, e221.

37. Rasa, S.; Nora-Krukle, Z.; Henning, N.; Eliassen, E.; Shikova, E.; Harrer, T.; Scheibenbogen, C.; Murovtska, M.; Prusty, B.K. Chronic viral infections in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *J. Transl. Med.* 2018, 16, 268. [CrossRef]

38. Morris, G.; Maes, M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. *Metab. Brain Dis.* 2014, 29, 19–36. [CrossRef]

39. Morris, G.; Stubbs, B.; Köhler, C.A.; Walder, K.; Slyepchenko, A.; Berk, M.; Carvalho, A.F. The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. *Sleep Med. Rev.* 2018, 41, 255–265. [CrossRef]

40. Fluge, Ø.; Mella, O.; Bruland, O.; Risa, K.; Dyrstad, S.E.; Alme, K.; Rekeland, I.G.; Sapkota, D.; Rosland, G.V.; Fosså, A.; et al. Metabolic profiling indicates impaired pyruvate dehydrogenase function in myalgic encephalopathy/chronic fatigue syndrome. *JCI Insight* 2016, 1, e89376. [CrossRef] [PubMed]

41. Koufaki, P.; Naish, P.F.; Mercer, T.H. Reproducibility of exercise tolerance in patients with end-stage renal disease. *Arch. Phys. Med. Rehabil.* 2001, 82, 1421–1424. [CrossRef] [PubMed]
42. Selig, S.E.; Carey, M.F.; Menzies, D.G.; Patterson, J.; Geerling, R.H.; Williams, A.D.; Bamroongsuk, V.; Toia, D.; Krum, H.; Hare, D.L. Reliability of isokinetic strength and aerobic power testing for patients with chronic heart failure. *J. Cardiopulm. Rehabil.* 2002, 22, 282–289. [CrossRef] [PubMed]

43. Hansen, J.E.; Sun, X.G.; Yasunobu, Y.; Garafano, R.P.; Gates, G.; Barst, R.J.; Wasserman, K. Reproducibility of cardiopulmonary exercise measurements in patients with pulmonary arterial hypertension. *Chest* 2004, 126, 816–824. [CrossRef] [PubMed]

44. Larson, B.; Davenport, T.E.; Stevens, S.R.; Van Ness, J.M.; Snell, C.R. Reproducibility of measurements obtained during cardiopulmonary exercise testing in individuals with and without fatiguing health conditions: A case series. *Cardiopulm. Phys. Ther. J.* 2019, 30, 145–152. [CrossRef]

45. Keller, B.A.; Pryor, J.L.; Giloteaux, L. Inability of myalgic encephalomyelitis/chronic fatigue syndrome patients to reproduce VO2peak indicates functional impairment. *J. Transl. Med.* 2014, 12, 104. [CrossRef] [PubMed]

46. van Campen, C.; Rowe, P.; Visser, F. Validity of 2-Day Cardiopulmonary Exercise Testing in Male Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Adv. Phys. Educ.* 2020, 10, 68–80. [CrossRef]

47. Naviaux, R.K.; Naviaux, J.C.; Li, K.; Bright, A.T.; Alaynick, W.A.; Wang, L.; Baxter, A.; Nathan, N.; Anderson, W.; Gordon, E. Metabolic features of chronic fatigue syndrome. *Proc. Natl. Acad. Sci. USA* 2016, 113, E5472–E5480. [CrossRef]

48. Esfandyarpour, R.; Kashi, A.; Nemat-Gorgani, M.; Wilhelmy, J.; Davis, R.W. A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). *Proc. Natl. Acad. Sci. USA* 2019, 116, 10250–10257. [CrossRef]

**Publisher’s Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).